Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation - Report of a case with more than 4-year disease-free survival

被引:8
作者
Geffen, DB [1 ]
Benharroch, D
Yellin, A
Ariad, S
Or, R
Cohen, Y
机构
[1] Soroka Univ, Ctr Med, Dept Oncol, Beer Sheva, Israel
[2] Soroka Univ, Ctr Med, Dept Pathol, Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
[4] Chaim Sheba Med Ctr, Dept Thorac Surg, IL-52621 Tel Hashomer, Israel
[5] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[6] Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel
[7] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2001年 / 24卷 / 06期
关键词
thymic carcinoma; neoadjuvant; high-dose chemotherapy; radiation therapy;
D O I
10.1097/00000421-200112000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymic carcinoma is a rare epithelial malignancy differentiated from thymoma by the presence of cytologically malignant cells. There are few reports of the treatment of locally advanced or metastatic thymic carcinoma. We describe a patient who sought treatment for thymic carcinoma metastatic to pleura, pericardium, retroperitoneum, and neck nodes. He was treated With neoadjuvant etoposide, ifosfamide, and cisplatin, and underwent resection. We then administered high-dose chemotherapy with autologous stem cell support, followed by radiation therapy. The patient remains in complete remission more than 4 years after diagnosis. To our knowledge, this is the first report of metastatic thymic carcinoma treated with neoadjuvant therapy and postoperative high-dose chemotherapy. Metastatic thymic carcinoma may be curable by aggressive combined therapies.
引用
收藏
页码:566 / 569
页数:4
相关论文
共 16 条
[1]   Thymic carcinoma: Current staging does not predict prognosis [J].
Blumberg, D ;
Burt, ME ;
Bains, MS ;
Downey, RJ ;
Martini, N ;
Rusch, V ;
Ginsberg, RJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 115 (02) :303-308
[2]   Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group [J].
Giaccone, G ;
Ardizzoni, A ;
Kirkpatrick, A ;
Clerico, M ;
Sahmoud, T ;
vanZandwijk, N .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :814-820
[3]  
Haim N, 1997, CANCER-AM CANCER SOC, V80, P1989, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1989::AID-CNCR17>3.0.CO
[4]  
2-U
[5]  
HANNA N, 2000, P AN M AM SOC CLIN, V19, pA59
[6]   Treatment of invasive thymoma with single-agent ifosfamide [J].
Highley, MS ;
Underhill, CR ;
Parnis, FX ;
Karapetis, C ;
Rankin, E ;
Dussek, J ;
Bryant, B ;
Rowland, C ;
Hodson, N ;
Hughes, J ;
Harper, PG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2737-2744
[7]   THYMIC CARCINOMA - 10 YEARS EXPERIENCE IN 20 PATIENTS [J].
HSU, CP ;
CHEN, CY ;
CHEN, CL ;
LIN, CT ;
HSU, NY ;
WANG, JH ;
WANG, PY .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 107 (02) :615-620
[8]   CISPLATIN PLUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN METASTATIC OR RECURRENT THYMOMA - FINAL RESULTS OF AN INTERGROUP TRIAL [J].
LOEHRER, PJ ;
KIM, K ;
AISNER, SC ;
LIVINGSTON, R ;
EINHORN, LH ;
JOHNSON, D ;
BLUM, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1164-1168
[9]   Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial [J].
Loehrer, PJ ;
Chen, M ;
Kim, KM ;
Aisner, SC ;
Einhorn, LH ;
Livingston, R ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3093-3099
[10]   INTRAPLEURAL PERFUSION HYPERTHERMO-CHEMOTHERAPY FOR MALIGNANT PLEURAL DISSEMINATION AND EFFUSION [J].
MATSUZAKI, Y ;
SHIBATA, K ;
YOSHIOKA, M ;
INOUE, M ;
SEKIYA, R ;
ONITSUKA, T ;
IWAMOTO, I ;
KOGA, Y .
ANNALS OF THORACIC SURGERY, 1995, 59 (01) :127-131